Table S1: Diagnostic procedures of AE-IPF

	Total	Europe	Asia	North America	South America	Oceania	Africa	p-value
HRCT / multislice thin-section CT (without contrast media)	76% (N=453)	67% (N=199)	91% (N=126)	71% (N=55)	81% (N=47)	71% (N=21)	80% (N=5)	< 0.001
CT with contrast media (even in the absence of clinical suspicion of pulmonary embolism)	34% (N=453)	45% (N=199)	20% (N=126)	33% (N=55)	34% (N=47)	33% (N=21)	20% (N=5)	< 0.001
Echocardiography	66% (N=453)	66% (N=199)	64% (N=126)	65% (N=55)	81% (N=47)	57% (N=21)	40% (N=5)	0.217
D-Dimer	64% (N=457)	71% (N=201)	67% (N=127)	49% (N=55)	68% (N=47)	27% (N=22)	40% (N=5)	< 0.001
Troponins	50% (N=457)	54% (N=201)	37% (N=127)	67% (N=55)	47% (N=47)	64% (N=22)	20% (N=5)	0.0013
NT-proBNP/BNP	72% (N=457)	73% (N=201)	72% (N=127)	76% (N=55)	72% (N=47)	73% (N=22)	20% (N=5)	0.1927
KL-6	18% (N=457)	6% (N=201)	51% (N=127)	4% (N=55)	6% (N=47)	0% (N=22)	0% (N=5)	< 0.001
Bronchoalveolar lavage always	6% (N=453)	5% (N=199)	10% (N=126)	4% (N=55)	6% (N=47)	0% (N=21)	0% (N=5)	0.311
Bronchoalveolar lavage only if infection is suspected and the patient is in an appropriate condition to undergo bronchoscopy	71% (N=453)	71% (N=199)	68% (N=126)	76% (N=55)	68% (N=47)	76% (N=21)	40% (N=5)	0.551
Sputum	85% (N=453)	87% (N=199)	91% (N=126)	84% (N=55)	68% (N=47)	81% (N=21)	60% (N=5)	0.003
Induced sputum	14% (N=453)	8% (N=199)	25% (N=126)	15% (N=55)	15% (N=47)	10% (N=21)	20% (N=5)	0.003
CMV-PCR/CMV pp65Ag	38% (N=452)	40% (N=199)	51% (N=126)	27% (N=55)	13% (N=46)	29% (N=21)	40% (N=5)	< 0.001
Pneumocystis jiroveci	60% (N=452)	58% (N=199)	68% (N=126)	53% (N=55)	52% (N=46)	62% (N=21)	20% (N=5)	0.091
Influenza	75% (N=452)	71% (N=199)	70% (N=126)	93% (N=55)	78% (N=46)	95% (N=21)	40% (N=5)	< 0.001
RSV	45% (N=452)	49% (N=199)	25% (N=126)	65% (N=55)	37% (N=46)	86% (N=21)	20% (N=5)	< 0.001

Table S2: Treatments of AE-IPF

	Total	Europe	Asia	North America	South America	Oceania	Africa	p-value
Prednisolone 1 mg / kg / day, followed by slow tapering (over weeks)	31% (N=450)	26% (N=199)	28% (N=124)	45% (N=55)	35% (N=46)	43% (N=21)	80% (N=5)	0.009
Methylprednisolone or equivalent 500 mg-1000 mg / day for 3 days, followed by slow tapering	63% (N=450)	59% (N=199)	70% (N=124)	56% (N=55)	67% (N=46)	62% (N=21)	40% (N=5)	0.268
Methylprednisolone or equivalent 500 mg-1000 mg / day pulsed for 3 days WITHOUT any tapering	11% (N=450)	17% (N=199)	6% (N=124)	4% (N=55)	9% (N=46)	10% (N=21)	0% (N=5)	0.023
Cyclosporin	9% (N=450)	1% (N=199)	30% (N=124)	0% (N=55)	0% (N=46)	0% (N=21)	0% (N=5)	< 0.001
Cyclophosphamide i.v. bolus	19% (N=450)	20% (N=199)	30% (N=124)	0% (N=55)	9% (N=46)	19% (N=21)	0% (N=5)	< 0.001
Tacrolimus	5% (N=450)	1% (N=199)	17% (N=124)	2% (N=55)	0% (N=46)	0% (N=21)	0% (N=5)	< 0.001
Rituximab	4% (N=450)	3% (N=199)	2% (N=124)	9% (N=55)	11% (N=46)	0% (N=21)	0% (N=5)	0.025
I never treat AE-IPF with any immunosuppressive therapy	4% (N=450)	4% (N=199)	4% (N=124)	2% (N=55)	0% (N=46)	10% (N=21)	0% (N=5)	0.447
Polymyxin B Hemoperfusion (or similar)	8% (N=445)	3% (N=199)	25% (N=122)	0% (N=54)	0% (N=44)	0% (N=21)	0% (N=5)	< 0.001

Recombinant Thrombomodulin	10% (N=445)	1% (N=199)	34% (N=122)	0% (N=54)	0% (N=44)	0% (N=21)	0% (N=5)	< 0.001
Plasmapheresis / plasma exchange	4% (N=445)	3% (N=199)	8% (N=122)	6% (N=54)	0% (N=44)	0% (N=21)	0% (N=5)	0.121
Broad-spectrum antibiotics combined with macrolides	56% (N=443)	53% (N=197)	53% (N=122)	61% (N=54)	61% (N=44)	76% (N=21)	40% (N=5)	0.303
Antibiotic treatment only when there is a clinical and/or laboratory indication for a bacterial infection	23% (N=443)	23% (N=197)	23% (N=122)	20% (N=54)	25% (N=44)	24% (N=21)	20% (N=5)	0.996
I would initiate either antifibrotic without preference	32% (N=439)	37% (N=196)	17% (N=121)	45% (N=53)	30% (N=43)	38% (N=21)	60% (N=5)	0.001
I do not see an indication for antifibrotic therapy at all in this situation	33% (N=439)	39% (N=196)	25% (N=121)	34% (N=53)	28% (N=43)	43% (N=21)	0% (N=5)	0.061
Always initiate or increase antacid drug therapy	19% (N=434)	16% (N=192)	23% (N=121)	11% (N=53)	31% (N=42)	14% (N=21)	20% (N=5)	0.105

Table S3: intensive and palliative care during AE-IPF

	Total	Europe	Asia	North America	South America	Oceania	Africa	p-value
Invasive Ventilation for all IPF patients	9% (N=434)	3% (N=192)	17% (N=121)	13% (N=53)	14% (N=42)	5% (N=21)	20% (N=5)	0.002
Invasive ventilation only to patients suitable for lung transplantation (LTX) as a bridge to LTX or very selected other patients	45% (N=434)	49% (N=192)	33% (N=121)	57% (N=53)	43% (N=42)	62% (N=21)	20% (N=5)	0.011
ECMO only to patients suitable for LTX as a bridge to LTX	44% (N=434)	57% (N=192)	31% (N=121)	47% (N=53)	33% (N=42)	24% (N=21)	40% (N=5)	< 0.001
High-flow oxygen	81% (N=434)	86% (N=192)	79% (N=121)	89% (N=53)	55% (N=42)	90% (N=21)	60% (N=5)	< 0.001
Non-invasive ventilation	74% (N=434)	68% (N=192)	77% (N=121)	77% (N=53)	81% (N=42)	81% (N=21)	60% (N=5)	0.296
Palliative care always/usually considered	65% (N=433)	66% (N=191)	66% (N=121)	66% (N=53)	50% (N=42)	71% (N=21)	60% (N=5)	0.451

Table S4: Prevention of AE-IPF

	Total	Europe	Asia	North America	South America	Oceania	Africa	p-value
If surgery is necessary, use of low tidal volume and avoidance of hyper-oxygenation to try to prevent injury	69% (N=429)	71% (N=189)	63% (N=119)	79% (N=53)	71% (N=42)	67% (N=21)	60% (N=5)	0.384
Preferentially use regional anesthesia ...	69% (N=429)	76% (N=189)	50% (N=119)	85% (N=53)	67% (N=42)	71% (N=21)	100% (N=5)	< 0.001
Any elective surgical procedures should be avoided ...	15% (N=429)	17% (N=189)	13% (N=119)	19% (N=53)	12% (N=42)	5% (N=21)	20% (N=5)	0.528
Antifibrotic therapy	86% (N=427)	92% (N=189)	79% (N=118)	87% (N=53)	83% (N=41)	81% (N=21)	60% (N=5)	0.021
Vaccination (influenza, pneumococcal, etc.)	93% (N=427)	95% (N=189)	89% (N=118)	94% (N=53)	93% (N=41)	86% (N=21)	100% (N=5)	0.273
Antacids medication (PPI, H2 blockers) in all IPF patients	52% (N=427)	47% (N=189)	52% (N=118)	57% (N=53)	59% (N=41)	67% (N=21)	80% (N=5)	0.273
Low dose steroids (<10mg) in all IPF patients	4% (N=427)	2% (N=189)	10% (N=118)	0% (N=53)	2% (N=41)	0% (N=21)	40% (N=5)	< 0.001
Anticoagulants in all IPF patients	2% (N=427)	1% (N=189)	3% (N=118)	2% (N=53)	2% (N=41)	0% (N=21)	0% (N=5)	0.900
Azithromycin long term / maintenance	7% (N=427)	8% (N=189)	9% (N=118)	0% (N=53)	7% (N=41)	5% (N=21)	0% (N=5)	0.317

Pulmonary rehabilitation or other forms of structured exercise therapy	58% (N=427)	61% (N=189)	51% (N=118)	57% (N=53)	59% (N=41)	67% (N=21)	60% (N=5)	0.582